Thermo Fisher Scientific, AbbVie, Danaher, Veeva Systems, and SpringWorks Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological processes and technologies—such as genetic engineering, cell culture, and molecular biology—to develop new drugs, therapies, and diagnostics. Their value often hinges on the success of clinical trials, regulatory approvals, and scientific breakthroughs. Because of their research-driven nature, biotech stocks can exhibit higher volatility but also the potential for substantial returns. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE:TMO traded down $0.35 during mid-day trading on Thursday, hitting $414.80. The company's stock had a trading volume of 818,055 shares, compared to its average volume of 1,918,504. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a fifty day moving average of $417.57 and a 200-day moving average of $493.84. The company has a market capitalization of $156.58 billion, a price-to-earnings ratio of 25.09, a P/E/G ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific has a fifty-two week low of $390.50 and a fifty-two week high of $627.88.
Read Our Latest Research Report on TMO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded down $0.11 during trading hours on Thursday, reaching $191.39. The company had a trading volume of 1,187,940 shares, compared to its average volume of 6,214,772. AbbVie has a one year low of $163.52 and a one year high of $218.66. The stock has a 50-day moving average of $183.78 and a two-hundred day moving average of $187.32. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The firm has a market capitalization of $338.07 billion, a PE ratio of 79.75, a PEG ratio of 1.62 and a beta of 0.50.
Read Our Latest Research Report on ABBV
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of Danaher stock traded up $0.26 during trading on Thursday, reaching $204.98. The company's stock had a trading volume of 955,732 shares, compared to its average volume of 4,275,572. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $146.70 billion, a P/E ratio of 38.82, a price-to-earnings-growth ratio of 2.66 and a beta of 0.77. The stock has a 50-day moving average price of $191.79 and a two-hundred day moving average price of $211.67. Danaher has a one year low of $171.00 and a one year high of $281.70.
Read Our Latest Research Report on DHR
Veeva Systems (VEEV)
Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.
Shares of VEEV stock traded up $0.75 during trading hours on Thursday, reaching $289.30. The company had a trading volume of 579,600 shares, compared to its average volume of 1,139,013. Veeva Systems has a 1-year low of $176.41 and a 1-year high of $291.68. The company has a 50 day moving average of $239.45 and a 200 day moving average of $231.56. The firm has a market cap of $47.07 billion, a price-to-earnings ratio of 71.43, a P/E/G ratio of 1.89 and a beta of 0.99.
Read Our Latest Research Report on VEEV
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
SWTX traded up $0.02 during midday trading on Thursday, reaching $46.77. 3,533,330 shares of the company were exchanged, compared to its average volume of 2,335,475. The stock has a market capitalization of $3.52 billion, a P/E ratio of -13.44 and a beta of 0.70. The stock's 50-day simple moving average is $43.64 and its 200 day simple moving average is $43.71. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $62.00.
Read Our Latest Research Report on SWTX
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
